JNK exacerbates ischemia/reperfusion injury in hyperglycemic subjects.
JNK exacerbates ischemia/reperfusion injury in hyperglycemic subjects.
批准号:
7851408
负责人:
KEITH A WEBSTER
金额:
$47.81万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2012-06-30
关键词:
Acute myocardial infarctionAffectAnimal ModelApoptosisApoptoticBlood VesselsBrainCardiacCardiac MyocytesCaspaseCellsCessation of lifeDropsEchocardiographyEtiologyEvans blue stainFastingGene ExpressionGlucoseGlycolysisHeartHyperglycemiaHyperglycemic MiceImageImaging TechniquesInfarctionInjuryInsulinInsulin ResistanceIschemiaLipidsLiverLong-Term EffectsMagnetic Resonance ImagingMediatingMetabolicMetabolic stressMitochondriaModelingMolecularMusMuscleMuscle CellsMyocardialMyocardial InfarctionMyocardial IschemiaMyocardiumObesityOutcomeOxidative StressPathway interactionsPatientsPhosphorylationPhosphotransferasesPredispositionProductionRadioisotopesReperfusion InjuryReperfusion TherapyReportingResearchRoleSerineSignal TransductionStagingStaining methodStainsStressTechniquesTestingTimeTissuesTracerWild Type Mousebasedb/db mouseextracellularfallsglucose metabolismglucose transportin vivoinorganic phosphateinsulin receptor substrate 1 proteinkinase inhibitormouse modelnovel strategiesoutcome forecastprogramspublic health relevanceradiotracerresearch studystress-activated protein kinase 1
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The mean time to reperfusion of acute myocardial infarction patients in the USA is 3-4h. The metabolic activity within the ischemic tissue over this period is a major determinant of outcome and is critically influenced by the glycemic and insulin responsive status of the subject. Inadequate glucose-stimulated insulin production and/or insulin resistance of muscle and liver cause hyperglycemia. We hypothesize that the exacerbated injury that accompanies myocardial ischemia/reperfusion in hyperglycemic subjects is at least in part the consequence of an early switch in the function of c-Jun-N-terminal kinase (JNK) from pro-survival to pro-death. We previously described an energy-dependent switch in the function of JNK in cultured cardiac myocytes. The switch occurred when cardiac myocyte ATP level fell by below 50%, a condition that sensitized myocytes to oxidative stress, and coincided with increased phosphorylation of the insulin receptor substrate-1 (IRS-1) on the inhibitory serine-307. We have now confirmed that the switch also operates in vivo when the myocardium is subjected to ischemia/reperfusion and encounters similar metabolic stress. The in vivo effect is dramatic, JNK inhibition during prolonged ischemia reduced both apoptosis and infarction by ~50%, but the same inhibition imposed on a short ischemic episode increased apoptosis >3-fold and infarct >2-fold. Because >50% of injury caused by severe ischemia/reperfusion is regulated by JNK, the switch is potentially a major contributor to the outcome of AMI. In this revised application we will determine the degree to which the etiology of hyperglycemia affects JNK metabolic switching, characterize the metabolic signals that mediate switching and determine the death/survival pathways that are affected. In Aim 1 we will determine infarction and remodeling over time by high-definition echocardiography and micro-MRI. This will be implemented in 3 models of hyperglycemia: (i) db/db mice with monogenetic susceptibility to obesity and insulin resistance. (ii) NONcNZO10 mice with polygenic susceptibility to obesity and insulin resistance. (iii) Wild type mice infused with lipid to induce insulin resistance and hyperglycemia. In Aim 2 we will use advanced imaging techniques including micro-NMR/MRI to determine the precise metabolic parameters that regulate JNK switching in normal and hyperglycemic hearts subjected to ischemia/reperfusion. In Aim 3 we will define the death pathways that are affected by the JNK switch and the long-term effects on remodeling and gene expression in the affected region of the myocardium. PUBLIC HEALTH RELEVANCE: Fasting hyperglycemia is associated with increased myocardial infarction in both animal models and patients. Fasting hyperglycemia is also associated with insulin resistance. The mechanism for the poor outcome of hyperglycemic patients to acute myocardial infarction is not known. Here we present a new hypothesis where stress kinases are activated specifically in hyperglycemic patients undergoing AMI and cause poor outcome. Experiments are proposed to test this hypothesis in mouse models. If our hypothesis is correct we will described the molecular basis for this an begin to develop new approaches for treatment.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
JNK exacerbates ischemia/reperfusion injury in hyperglycemic subjects.
-
批准号:7663609
-
项目类别:
-
资助金额:$47.81万
-
财政年份:2009
-
负责人:KEITH A WEBSTER
-
依托单位:
Regulated Therapeutic Angiogenesis: for Ischemic Disease
-
批准号:7035895
-
项目类别:
-
资助金额:$36.51万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Regulated Therapeutic Angiogenesis: for Ischemic Disease
-
批准号:6598552
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Micro-RNA reprogrammed human CD34 stem cells for cardiovascular disease therapy
-
批准号:8105927
-
项目类别:
-
资助金额:$39.4万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Regulated Therapeutic Angiogenesis: for Ischemic Disease
-
批准号:6857119
-
项目类别:
-
资助金额:$37.39万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Micro-RNA reprogrammed human CD34 stem cells for cardiovascular disease therapy
-
批准号:8527943
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Micro-RNA Reprogrammed Human CD34 Stem Cells for Cardiovascular Disease Therapy
-
批准号:8656726
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Micro-RNA Reprogrammed Human CD34 Stem Cells for Cardiovascular Disease Therapy
-
批准号:8461966
-
项目类别:
-
资助金额:$43.84万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Regulated Therapeutic Angiogenesis: for Ischemic Disease
-
批准号:6727699
-
项目类别:
-
资助金额:$37.3万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Micro-RNA reprogrammed human CD34 stem cells for cardiovascular disease therapy
-
批准号:8299087
-
项目类别:
-
资助金额:$39.4万
-
财政年份:2003
-
负责人:KEITH A WEBSTER
-
依托单位:
Therapeutic angiogenesis to treat ischemic disorders
-
批准号:6528213
-
项目类别:
-
资助金额:$15.15万
-
财政年份:2001
-
负责人:KEITH A WEBSTER
-
依托单位:
Therapeutic angiogenesis to treat ischemic disorders
-
批准号:6400202
-
项目类别:
-
资助金额:$15.15万
-
财政年份:2001
-
负责人:KEITH A WEBSTER
-
依托单位:
REDOX STRESS COMPONENTS OF DEGENERATIVE HEART DISEASE
-
批准号:2002136
-
项目类别:
-
资助金额:$7.65万
-
财政年份:1996
-
负责人:KEITH A WEBSTER
-
依托单位:
CARDIOCYTE RESPONSES TO HYPOXIA
-
批准号:2449145
-
项目类别:
-
资助金额:$23.0万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
CARDIOCYTE RESPONSES TO HYPOXIA
-
批准号:2637605
-
项目类别:
-
资助金额:$26.97万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
CARDIOCYTE RESPONSES TO HYPOXIA
-
批准号:6043763
-
项目类别:
-
资助金额:$28.6万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
CARDIOCYTE RESPONSES TO HYPOXIA
-
批准号:3473054
-
项目类别:
-
资助金额:$19.32万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
Pathways of Apoptosis in Hypoxic Cardiac Myocytes
-
批准号:7052855
-
项目类别:
-
资助金额:$32.81万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
Mechanisms of action and activation of the death-inducing protein Bnip3
-
批准号:7406114
-
项目类别:
-
资助金额:$38.25万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
Mechanisms of action and activation of the death-inducing protein Bnip3
-
批准号:8052960
-
项目类别:
-
资助金额:$42.08万
-
财政年份:1990
-
负责人:KEITH A WEBSTER
-
依托单位:
海外基金